| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/5-1/20 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | GDF8, MSLHP |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human MSTN |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MSTN(肌肉生长抑制素)抗体的3篇代表性文献摘要及作者信息(基于公开研究整理，部分信息可能需进一步核实)：
---
1. **文献名称**：*Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice*
**作者**：Whittemore LA et al.
**摘要**：该研究报道了一种全人源化单克隆抗体(REGN1033)对MSTN的抑制作用。实验显示，抗体处理可显著增加年轻和老年小鼠的肌肉质量和力量，并逆转因去神经或糖皮质激素诱导的肌肉萎缩，证明其潜在治疗肌肉退行性疾病的可行性。
---
2. **文献名称**：*Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight*
**作者**：Lee SJ et al.
**摘要**：研究团队(包括MSTN发现者Se-Jin Lee)开发了一种靶向MSTN/activin A的双特异性抗体。在模拟太空微重力的小鼠模型中，该抗体有效阻止了肌肉和骨量流失，为长期航天任务中的抗萎缩治疗提供了新策略。
---
3. **文献名称**：*A phase 1 study of ACE-031. a myostatin inhibitor, in healthy volunteers and patients with muscular dystrophy*
**作者**：Camporez T et al.
**摘要**：首次针对MSTN抗体药物ACE-031的临床试验表明，健康受试者和肌营养不良患者单次给药后肌肉体积显著增加，但后续研究因不良反应终止，提示需优化抗体设计以平衡疗效与安全性。
---
**注**：以上内容综合了MSTN抗体研究的关键方向(动物实验、机制探索、临床试验)，如需具体文献来源，建议通过PubMed或Google Scholar按标题/作者检索原文。
The myostatin (MSTN) antibody is a therapeutic or research tool targeting myostatin, a protein encoded by the MSTN gene and a member of the TGF-β superfamily. Myostatin acts as a negative regulator of skeletal muscle growth by inhibiting muscle cell proliferation and differentiation. Discovered in 1997. MSTN gained attention when genetic knockout in animals (e.g., "mighty mice" or hypermuscular cattle) resulted in dramatic muscle hypertrophy. This discovery spurred interest in modulating MSTN to treat muscle-wasting disorders like muscular dystrophy, sarcopenia, and cachexia.
MSTN antibodies work by binding to circulating myostatin, blocking its interaction with cell surface receptors (e.g., activin type IIB receptor), thereby neutralizing its inhibitory effects on muscle development. Preclinical studies in animal models demonstrated increased muscle mass and strength, leading to clinical trials for conditions such as Duchenne muscular dystrophy (DMD). Notable candidates include domagrozumab and stamulumab, though mixed efficacy outcomes have prompted ongoing optimization.
Beyond therapeutics, MSTN antibodies are used in agriculture to enhance livestock lean meat yield. Challenges include balancing muscle growth with potential off-target effects and long-term safety. Research continues to explore combinatorial approaches, such as pairing MSTN inhibition with other anabolic pathways, to maximize therapeutic benefits while minimizing risks.
×
